Patents by Inventor Wayne Hancock

Wayne Hancock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of using interleukin-2 agents
    Patent number: 12642840
    Abstract: The present invention provides, among other things, methods of using IL-2 fusion proteins, comprising an IL-2 variant and an Pc region, to treat and/or prevent heart transplant rejections. Methods of treating heart disease or a symptom thereof, conditioning a subject for heart transplant, modulating immunosuppression, and selectively increasing regulatory T cells are also disclosed.
    Type: Grant
    Filed: December 1, 2022
    Date of Patent: June 2, 2026
    Assignees: Visterra, Inc., The Children's Hospital of Philadelphia
    Inventors: Gregory Babcock, Wayne Hancock
  • METHODS OF USING INTERLEUKIN-2 AGENTS
    Publication number: 20240041981
    Abstract: Methods of using IL-2 fusion proteins to treat and/or prevent transplant rejection such as heart transplant rejection are disclosed.
    Type: Application
    Filed: December 1, 2022
    Publication date: February 8, 2024
    Inventors: Gregory Babcock, Wayne Hancock
  • COMPOSITIONS AND METHODS FOR MODULATION OF SUPPRESSOR T CELL ACTIVATION
    Publication number: 20100061984
    Abstract: Methods of treating autoimmune disorders, coronary artery disease, allergy symptoms, allograft rejection sepsis/toxic shock are disclosed. Some methods comprise administering one or more regulatory compositions to activate the T suppressor cells by increasing the acetylation level and/or protein level of FOXP3 in combination with a T suppressor stimulus and/or an antigen. Some methods comprise administering one or more regulatory compositions to activate the T suppressor cells by increasing the acetylation level and/or protein level of FOXP3. Some methods comprise administering soluble GITR or antibodies that bind to GITR ligand. Methods of treating cancer, infectious diseases, and immune deficiency are also disclosed as are vaccination methods. The methods comprise administering one or more regulatory compositions to inactivate the T suppressor cells by reducing the acetylation level and/or protein level of FOXP3. Improved vaccines and vaccination methods are disclosed.
    Type: Application
    Filed: January 22, 2007
    Publication date: March 11, 2010
    Applicants: The Trustees of the University of Pennsylvania, The Children's Hospital of Philadelphia
    Inventors: Mark L. Greene, Sandra W. Saouaf, Bin Li, Hongtao Zhang, Wayne Hancock
  • Substituted beta carbolines
    Publication number: 20060166978
    Abstract: The subject matter of the present invention is directed to novel substituted beta-carbolines, and specifically compounds of the formula I, which are suitable for the production of pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of I?B kinase is involved.
    Type: Application
    Filed: March 28, 2006
    Publication date: July 27, 2006
    Inventors: Olaf Ritzeler, Alfredo Castro, Louis Grenier, Francois Soucy, Wayne Hancock, Hormoz Mazdiyasni, Vito Palombella, Julian Adams
  • Methods and compositions for the treatment or prevention of immune disorders using combination therapy
    Publication number: 20030215442
    Abstract: The present invention provides methods of suppressing immune disorders such as allograft rejection in a patient by a combination of inhibition of the binding of LIGHT to HVEM and immunosuppressive therapy. Various therapeutic regimens are provided. The present invention further provides kits and pharmaceutical compositions useful in the present methods.
    Type: Application
    Filed: February 19, 2003
    Publication date: November 20, 2003
    Inventors: Christopher C. Fraser, Wayne Hancock